Assessment of the Proliferative Marker Ki-67 and p53 Protein Expression in HBV- and HCVrelated
Abstract
Background: Chronic HBV and HCV infections are the major risk factors for the development of HCC through a multistep
pathway that involves viral and non-viral dependent pathophysiological steps. Hepatic expression of the nuclear proliferative
marker ki-67 and the p53 oncoprotein were found to be associated with poor outcome. So, the present study was done to evaluate
the changes in expression of Ki-67 and p53 oncoprotein, and to determine p53 gene mutation in HBV/HCV-related HCC Egyptian
patients.
Methods: Eight HBV-and 22 HCV-positive HCC cases have been examined for the presence of p53 mutation by
immunohistochemistry (IHC) and single-strand conformation polymorphism (SSCP), followed by direct DNA sequencing. HCV
were genotyped by LiPA-II.
Results: Our results have shown that the proliferative marker ki-67 LI and p53 were highly expressed and signicantly related to
tumor grade in the Egyptian HCC cases (p<0.05). Also, p53 mutation was found in 16 HCC cases by IHC and in 14 HCC cases
by SSCP, only 11 patients showed p53 mutation by sequencing. The highest mutation rate was scored for exon 7 (7 mutations)
at codon 249; 4 out of 8 (50%) of HBV-related HCC cases and 3 out of 22 (13.6%) of HCV-related HCC cases, followed by exon
5 (3 mutations) at codons 133, 146, 176 in HCV-related HCC cases, then exon 8 at codon 275 in HCV-related HCC cases. The
concordance between the IHC and sequencing analysis was 69%.
Conclusion: The present study demonstrates the association between the proliferative marker ki-67 and p53 expression with the
tumor grade of Egyptian HBV/HCV-related HCC cases. Our results also support the hypothesis that p53 mutations are rather a
late event in the carcinogenesis. Also, they suggest that the nal steps of hepatocarcinogenesis are common and independent of
the aetiology of the viral infection.
pathway that involves viral and non-viral dependent pathophysiological steps. Hepatic expression of the nuclear proliferative
marker ki-67 and the p53 oncoprotein were found to be associated with poor outcome. So, the present study was done to evaluate
the changes in expression of Ki-67 and p53 oncoprotein, and to determine p53 gene mutation in HBV/HCV-related HCC Egyptian
patients.
Methods: Eight HBV-and 22 HCV-positive HCC cases have been examined for the presence of p53 mutation by
immunohistochemistry (IHC) and single-strand conformation polymorphism (SSCP), followed by direct DNA sequencing. HCV
were genotyped by LiPA-II.
Results: Our results have shown that the proliferative marker ki-67 LI and p53 were highly expressed and signicantly related to
tumor grade in the Egyptian HCC cases (p<0.05). Also, p53 mutation was found in 16 HCC cases by IHC and in 14 HCC cases
by SSCP, only 11 patients showed p53 mutation by sequencing. The highest mutation rate was scored for exon 7 (7 mutations)
at codon 249; 4 out of 8 (50%) of HBV-related HCC cases and 3 out of 22 (13.6%) of HCV-related HCC cases, followed by exon
5 (3 mutations) at codons 133, 146, 176 in HCV-related HCC cases, then exon 8 at codon 275 in HCV-related HCC cases. The
concordance between the IHC and sequencing analysis was 69%.
Conclusion: The present study demonstrates the association between the proliferative marker ki-67 and p53 expression with the
tumor grade of Egyptian HBV/HCV-related HCC cases. Our results also support the hypothesis that p53 mutations are rather a
late event in the carcinogenesis. Also, they suggest that the nal steps of hepatocarcinogenesis are common and independent of
the aetiology of the viral infection.
Mohamed, W. S., Omar, M. M., Khayri, T. M., & Fakhi, I. M. (2008). Assessment of the Proliferative Marker Ki-67 and p53 Protein Expression in HBV- and HCVrelated. International Journal of Health Sciences, 2(1). Retrieved from https://pub.qu.edu.sa/index.php/journal/article/view/66
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
Copyright and license info is not available